Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good morning yall. Time to get the rear in gear!!!!!!!!!!!!!!!!!!!!!
Thta's gutsy Salty. 1 person operation, negative revenues, development stage and a few hundred million o/s. What's in your coffee cup this morning?
On that news and an initial scan OCLG looks like a possibility. Thanks. I'll dive deeper
TY for bringing OCLG to everyone's attention Gen. I've only taken an initial glance but there does seem to be potential with this one and maybe a lot of potential.
Let's see if OCLG will earn 540,000 in 2014.I like the pps I would like it better,if the company was profitable now.
Oncologix Tech Acquires Amian Health Services; Gains Leading Veterans and Private Pay Healthcare Service Company
ALEXANDRIA, LA--(Marketwired - Dec 17, 2013) - Oncologix Tech, Inc. (OTCQB: OCLG) announced today the Company has purchased the assets of Amian Health Services, a leader in the Personal Care Attendant (PCA) healthcare services industry for Veterans and Private Pay clients.
Wayne Erwin, OCLG's Chief Executive Officer, remarked, "Oncologix is extremely delighted to complete this acquisition of Amian Health Services. Amian is a leading healthcare services company in the State of Louisiana that provides PCA services to over 70 active clients, 78 full time employees, and with $1.06 million in annual revenues. The acquisition of Amian Health will provide the delivery of personal care services to Private Pay and Veterans clients with a market segment that Angels of Mercy did not serve. We will merge the Amian operations and selected personnel into Angels of Mercy existing operations and the combined synergies of both business entities will provide over $4.1 million in annual revenues, 228 employees and earnings to exceed $540,000 per year. This acquisition continues with our healthcare division strategy: to acquire healthcare services-related companies."
Amian Health Services began its healthcare service operations in 2004 with offices located in Alexandria and Lafayette, Louisiana. As a healthcare service provider, Amian delivers education and training to Personal Care Assistants who provide routine health and personal care support with Activities of Daily Living (ADL) to seniors, clients with physical impairments or disabilities in private homes, nursing care facilities, hospice care settings, and other residential settings. Amian holds both PCA-Medicaid Waiver Provider and Residential Rehabilitation/Supervised Independent Living (SIL), and personal care services for Veterans with licenses issued by the Division of Licensing and Certification of the Department of Social Services, Veterans Hospital Administration Social Services and the Louisiana Department of Health and Hospitals. Licenses are issued to Amian Health in Region 4 and Region 6 covering 12 parishes within the State of Louisiana.
Well, I just bought a butt load of this stuff shortly after the opening bell.
KBLB
Company Background
Kraig Biocraft Laboratories, Inc. is a development-stage company. It develops protein-based fibers, using recombinant deoxyribonucleic acid (DNA) technology, for commercial applications in both the specialty fiber and technical textile industries. The Company uses genetic engineering technologies to develop fibers with greater strength, resiliency and flexibility for use in its target markets, namely the textile, specialty fiber and technical textile industries. The technical textile industry involves products for both industrial and consumer products, such as filtration fabrics, medical textiles, safety and protective clothing and fabrics used in defense and military. The Company focuses on its work on the creation of new fibers with properties including fibers with potential performance and technical fiber applications.
http://www.kraiglabs.com
NIMU
Company Background
Non-Invasive Monitoring Systems, Inc. (NIMS) along with its subsidiaries, is engaged in the research, development, manufacturing and marketing of a line of motorized, non-invasive, whole body, periodic acceleration platforms, which are intended as aids to increase local circulation and temporary relief of minor aches and pains, produce local muscle relaxation and reduce morning stiffness. The Company's products are derivatives of its original acceleration platform, the AT-101, and are for use in homes, wellness centers and clinics. NIMS is focused on developing and marketing its Exer-Rest line of acceleration therapeutic platforms based upon whole body periodic acceleration (WBPA) technology. The Exer-Rest line of acceleration therapeutic platforms includes the Exer-Rest AT, AT3800 and AT4700 models. In addition, it receives royalty revenue from the sales of non-invasive diagnostic monitoring devices and related software.
http://www.nims-inc.com
BZNE
Company Background
Biozone Pharmaceuticals, Inc. (Biozone Pharma), formerly International Surf Resorts, Inc., through its wholly owned subsidiary, BioZone Laboratories, Inc., which primarily is engaged in the business of developing and manufacturing over the counter (OTC) drug products and cosmetic and beauty products on behalf of third parties. In addition, through Biozone Pharma's wholly owned subsidiaries, Equalan LLC and Baker Cummins Corp., the Company markets two lines of skin care products. Its other activities include the sale by its wholly owned subsidiary, Equachem LLC, of raw materials used in OTC drugs and cosmetic products, and the research and development of certain drug delivery technology. On May 16, 2011, it acquired Aero Pharmaceuticals, Inc. On June 30, 2011, it acquired 100% interest in BioZone Laboratories, Inc.; 100% interests of Equalan, LLC and Equachem, LLC, and 45% interests of BetaZone, LLC. In December 2011, it transferred its 55% ownership in ISR de Mexico, S. R.L. de C. V.
It's butt bouncin' time yall. Let's get to it!!!!!!!!!!!!!!!!!!!!
illegal, 56Chevy informed me about the shopping spree and provided me with the link. I hope the pps does not move up to much before the company becomes profitable.The company own alot of property and I like that.
You are correect on their assest and lack of profits. I skimmed a couple of the latest (year old) 10Q's and 10K's. The losses may be due to their shopping spree in 2011 and 2012 buying up assets. Apparently, the current late filings are a consequence of a recent re-audit of past filings.
illegal,I will not purchase shares at the present because the company is not profitable.Things are expected to turn around in 2014.I will keep my eyes on UGHS.I believe UGHS own hospitals and assisted living facilities.
UGHS - I don't like that they are 2 quarterly filings behind, but there is a conf call today in 15 minutes about that issue. See http://www.sec.gov/Archives/edgar/data/1383960/000110262413001522/universitygeneralhealthsyste.htm
UGHS one to watch. http://ih.advfn.com/p.php?pid=nmona&article=59686842
Phil Frost stocks - Dr. Frost seems to have a golden touch when it comes to stocks. Not always, but impressively more often than not. That's why they are worth investigating. To wit, look at 2013 charts for ROX, OPKO, and LTS.
I culled thru the health/med/biotech holdings listed on the Phil Frost Plays board (http://investorshub.advfn.com/Phillip-Frost-Plays-27154) and sorted out non-healthcare and those over $5. Here's what we have to investigate:
BZNE, NIMU, CDOM, CDXC, KDUS, RXII, GALE.
Game on!
Article
Genetic Technologies Announces Share Reduction Schedule With Major Shareholder
18 hours 52 minutes ago - DJNF
Genetic Technologies Announces Share Reduction Schedule With Major Shareholder
MELBOURNE, AUSTRALIA--(Marketwired - Dec 18, 2013) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that entities associated with the Company's founder and largest shareholder, Dr. Mervyn Jacobson (collectively, the "Jacobson Entities"), have entered into several transactions which will result in the disposal of 105,937,500 shares in the Company. As a result, Dr. Jacobson's beneficial interest in the issued capital of the Company will be reduced from 23.83% to 6.15%.
The various transactions have been summarized as follows:
1. On December 17, 2013, the Jacobson Entities disposed of 30,000,000 shares
in GTG. These shares were crossed on the Australian Securities Exchange
at 4:55pm yesterday.
2. The Jacobson Entities and GTG have entered into a binding Share Exchange
Agreement ("Agreement") pursuant to which, subject to GTG shareholder
approval, the following transactions will occur:
1. The Jacobson Entities will exchange a total of 75,937,500 shares
in GTG at an agreed price of $0.08 per share for 4,500,000 shares
in ImmunAid Limited ("ImmunAid") owned by GTG at an agreed price
of $1.35 per share. As at the date of the Agreement, the shares in
ImmunAid held by GTG had a carrying value in the Company's balance
sheet of approximately $0.84 per share.
2. The Jacobson Entities, as interested parties, will not be able to
vote at the GTG shareholder meeting to consider the approval of
the Agreement.
3. ImmunAid and GTG have now executed an Option Agreement pursuant to
which ImmunAid will, when completion occurs under the Agreement,
grant to GTG a total of 2,250,000 options to acquire ordinary
shares in ImmunAid. Each option will entitle GTG to acquire one
ordinary share in ImmunAid at a price of $1.35 per share at any
time for three years from the date on which the options are
granted.
4. In consideration for the options granted to GTG by ImmunAid in
point (c), GTG agrees to pay ImmunAid an option fee of $500,000,
of which $351,618 will be satisfied by the forgiveness of
outstanding debts currently owed to GTG by ImmunAid. GTG will pay
the remaining $148,382 owed on the option fee in cash.
5. ImmunAid agrees that the $148,382 paid in cash by GTG will be used
solely for the payment of expenses to independent third parties
and that none of it will be used to pay fees to any related
parties of ImmunAid (for example, directors or major
shareholders).
6. All of the transactions above are subject to:
-- The receipt by GTG of an acceptable independent valuation
of the Company's 4,500,000 shares in ImmunAid and an
accompanying independent expert's fairness report in
respect of the transaction from the perspective of the GTG
shareholders;
-- The receipt of all necessary regulatory approvals, where
required; and
-- The receipt of the approval of the Company's shareholders
at an Extraordinary General Meeting to be convened as soon
as practicable (pursuant to ASX Listing Rule 10.1) at which
the Jacobson Entities will be unable to vote.
Assuming the transactions proceed as outlined above, the number of ordinary issued shares in GTG will fall by 13.26% from 572,694,121 to 496,756,621, following the cancellation of the shares acquired from the Jacobson Entities.
At the conclusion of the various transactions contemplated above, the Jacobson Entities will retain a total of 30,536,184 ordinary shares in GTG representing 6.15% of the Company's then total issued capital and Dr. Jacobson will continue his current active role for GTG as Vice President, Global Licensing and IP and also as CEO of ImmunAid Limited.
The Company will provide an update for shareholders on the timetable for implementation of the above transactions as soon as practical after engagement of the independent expert.
With the release of this announcement, the current trading halt can now be lifted.
About Genetic Technologies Limited
Genetic Technologies is an established diagnostics company with more than 20 years of experience in commercializing genetic testing, non-coding DNA and product patenting. The Company has operations in Australia and the U.S. and is dual-listed on the ASX (Code: GTG) and NASDAQ (Ticker: GENE). Genetic Technologies is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets. Its U.S. subsidiary, Phenogen Sciences Inc., offers novel predictive testing and assessment tools to help physicians proactively manage women's health. Phenogen's lead product, BREVAGen(TM), is a first in class, clinically validated risk assessment test for non-familial breast cancer.
For more information, please visit http://www.gtglabs.com and http://www.phenogensciences.com
Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.
FOR INFORMATION REGARDING THIS ANNOUNCEMENT PLEASE CONTACT
Tom Howitt
Chief Executive Officer (Acting)
Genetic Technologies Limited
Phone: +61 3 8412 7000
Laura Forman (USA)
Blueprint Life Science Group
+1 (415) 375 3340, Ext. 103
(MORE TO FOLLOW) Dow Jones Newswires
December 18, 2013 13:57 ET (18:57 GMT)
Over time, we'll probably have a few of those guys visiting the board. We will all need to remember to be very wary of their "hot tips".
LOL, mediconista. Let's not forget shamans, brujas, santeros and snake oil salesmen.
Good morning Medanistas. Time to hop out of the sack and begin researching health stocks.
When I first got my Scottrade account, almost three years ago, two of the first stocks I bought was GENE and NSPH. I made over 200% on both of these bad boys. I can assure you it was much more luck than skill but regardless of what it was, maybe these two can shine again.
GENE
Company Background
Genetic Technologies Limited (GTG) is engaged the provision of genetic testing services. The Company also conducts out-licensing program in respect of its non-coding deoxyribonucleic acid technology and supports a late-stage research project. The Company operates in three segments: Operations, Licensing and Research. The principal geographic segments of the Company include Australia, with the Company's headquarters being located in Melbourne in the State of Victoria. The Operations segment includes the provision of a range of genetic testing services. The Licensing segment includes the out-licensing of the Group's non-coding technology. The Research segment includes the undertaking of a range of research and development projects in the field of genetics and related areas. During the fiscal year ended June 30, 2012, the Company launched its new, predictive risk test, BREVAGen. BREVAGen is the clinically validated breast cancer predictive risk assessment tool.
http://www.gtglabs.com
NSPH
Company Background
Nanosphere, Inc. develops, manufactures and markets a molecular diagnostics platform, the Verigene System. The Company's nanoparticle technology provides the ability to run multiple tests simultaneously on the same sample. The Verigene System includes a bench-top molecular diagnostics workstation that is a universal platform for genomic and protein testing. The Verigene System is consists of a microfluidics processor, a touchscreen reader and disposable test cartridges. The Verigene System provides for multiple tests to be performed on a single platform, including both genomic and protein assays, from a single sample. The Company developed and launched a second generation Verigene System processor (the Processor SP) that handles the same processing steps as the Original Processor and incorporates sample preparation.
http://www.nanosphere.us.
I put AOLS on my watch list almost three years ago shortly after buying my first shares of LTS. The two had/have a connection but I can't remember what it was. Maybe Frost was buying shares. I never put too much thought into this one but since Frost was/is interested, we should probably at least investigate.
Company Background
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead compound, AEOL 10150, is entering human clinical trials in oncology where it is used in combination with radiation therapy. AEOL 10150 had been tested in two Phase-I clinical trials. The compound is also being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (pulmonary acute radiation syndrome or Lung-ARS), as well as the gastrointestinal sub-syndrome of acute radiation syndrome (GI-ARS). It is also being developed for use as a countermeasure for exposure to chemical vesicants, such as chlorine gas and sulfur mustard gas. These compounds, known as metalloporphyrins, scavenge reactive oxygen species (ROS) at the cellular level, mimicking the effect of the body's own natural antioxidant enzyme superoxide dismutase (SOD). Its lead compound, AEOL 10150, is a metalloporphyrin designed to neutralize reactive oxygen and nitrogen species.
http://www.aeoluspharma.com
I guess I'll have to start looking for a med stock.
IT Storage and IT Security might be among the first places to look:
http://www.latimes.com/business/la-fi-exchange-names-disclosed-20131207,0,1224576.story#axzz2mz2LmaXs
But, as I read somewhere else, hackers may be second inline behind government officials who are handing out the info. At any rate, IT storage is going to be needed for all the new records of people and because Obamacare also mandates the conversion to Electronic Health Records.
There amy als be unintended opportunities in the veterinary medicine sector:
http://www.foxnews.com/politics/2013/11/21/colorado-man-informed-his-dog-has-successfully-signed-up-for-obamacare/
Are your pets covered?
Thanks, please mark the board as a follower.
Welcome to the Obamacare Stock Portfolio Emergency Room
The Next Big Thing 2014.
Looking forward to 2014, let's put our collective wisdom together for our mutual benefit to figure out on how to make $$ on the Next Big Thing. Next Big Things are often what are called "disruptive", primarily from a technology point of view that quickly translates into economic opportunity. Railroads and electricity were the disruptive opportunities of the 19th century creating the Carnegies and Rockefellers. The Internet, bubble and all, was the disruptive technology of the late 20th century creating a lot of dot.com millionaires. Remember when you bought a POS pinkie on a rumor that they might open an online retail site? A couple of weeks later they announced it and it went 5X PPS even though they hadn't sold a single item. For the 21st century many of us made some $$ year spotting some diamonds in the rough that survived The Great Recession. This time it was not technology based, just pure business opportunity.
So, IMO, the Next Big Thing is also a disruptive business opportunity, but not technology based. Like it or not, regardless of your political leanings (whether you are a rabid Tea Partier or have a pin-up of Nancy Pelosi in your locker), Obamacare is here on New Year's Day, in time to get treated for hangovers. And, I believe there is opportunity there if we can figure it out, find whom to invest in and turn a profit. And, if you are one of the folks being forced into Obamacare, why not make it pay for itself?
Some facts and observations:
Obamacare is not healthcare reform. It is health insurance reform. The healthcare system will not change on Jan 1, just how the current self-insured, many small business employees and millions of currently insured will access healthcare and most importantly how it is paid for.
This is the biggest deal in healthcare payment and coverage since the enactment of Medicare in 1965.
25 million new currently uninsured patients will be placed into the system, many of whom have used minimal health services or none at all. Now that they are covered, expect them to use it a lot, lot more.
We have a national doctor shortage and, in many parts of the country, a shortage of nurses. Aproximately half of existing doctors aren't taking new patients. According to an article in the current Bloomberg Businessweek issue, the U.S. is expected to have 14% fewer doctors than needed to meet demand.
Many doctors do not take medicaid patients, so it is reasonable to expect many not to take Obamacare patients.
Bottom line: Demand for health services will outstrip supply.
The opportunity: some entreprenerial enterprising new businesses will spring up and some existing businesses will recognize and capitalize on this business opportunity. They will make $$.
Our job: figure out, early on, who they are, and invest early, and make $$ in 2014 and beyond. This isn't my realm of expertise, but I'm game at jumping in. Since Obamacare is already confusing, is being rolled out disastrously, and already creating scam artists, IMO there just has to be opportunity out here with legitimate publicly-traded providers.
Since 2014 is the initial year, a trial year and some extensions have been granted, the full impact won't start until 2015 and the opportunity may have a 3-5 year window.
Any thoughts? Any places to look at first?
I expect some of the usual suspects to be that for-profit hospital and clinic chains, testing labs and other direct service providers.
There should also be money in support industries. For example, IT will pay a big part to meet increased demands in billing, benefits management and electronic health records (EHRs). All of a sudden, the client base just grew about 25 million people and parts of Obamacare made certain mandates such as EHRs. www.forbes.com/sites/hardeepwalia/2013/10/14/how-to-profit-from-obamacare-whether-it-stays-or-is-repealed/
I suspect that medical supply companies (e.g. MCK – but out of my price league) are another sub-sector poised for growth as well as preventative practices. There may be consolidation – MSK bought PSSI earlier this year – so ops in the M&A sector, as well as start-ups.
All discussion welcome.
A brand spankin' new healthcare board... Great idea IA!!!
I'm the third poster... Not too shabby.
Thanks Genlou. I've been waiting to see if I would be notified when this board went live, but havene't been - or at least the email went somewhere else.
Please boardmark this board so we can see how many interested folks we have. Thanks.
illegal,LBMH $3.86 moved from the OTCBB to the nasdaq.Company pays .03 divdend.PPS make pull back some.
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
130
|
Created
|
12/16/13
|
Type
|
Premium
|
Moderator illegal_alias | |||
Assistants |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |